Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 puts, with total volume in those strikes near 1,000 ...

STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugsAppointment initiates ...

Cassava Sciences has faced a lot of scrutiny, with key figures resigning and the company settling an SEC penalty. Read what ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a modest uptick, ending the day at $26.91 which represents a slight increase of $0.77 or 2.95% from the prior close of $26.14. The stock opened at $26.

Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease ...

Cassava Sciences plans to pay a $40 million SEC investigation settlement, which has been placed in escrow. The company estimates its year-end cash balance to range from $117 to $127 million. The press ...